Skip to main content

Table 1 [A]: Descriptive characteristics of the patients included in the study; [B]: Linear regression model for the effect of various parameters in the upright RYAN score in the pre-defined cohort with 2-year follow-up

From: Laryngopharyngeal reflux in chronic obstructive pulmonary disease - a multi-centre study

[A]

Descriptive characteristics

All patients

n = 193

Pre-defined cohort with 2-year follow-up

n = 107

Age (years), mean (SD)

66.2 (8.8)

67.5 (8.4)

BMI (kg/m2), mean (SD)

27.1 (6.7)

27.8 (6.6)

Medical history of GERD, n (%)

33 (17)

16 (15)

Treated with PPI, n (%)

69 (37)

33 (30.8)

Gender, male (%)

119 (62)

75 (70)

Smoking status, n (%)

 Current

62 (34)

38 (36)

 Past

121 (66)

69 (64)

GOLD Stage, n (%)

 I

25 (14)

6 (6)

 II

82 (45)

58 (58)

 III

55 (30)

32 (32)

 IV

21 (11)

4 (4)

COPD Medication

 LABA

55 (28)

19 (18)

 LABA+ICS

151 (78)

102 (96)

 LAMA

129 (67)

81 (76)

 SABA

26 (13)

2 (2)

 SAMA

39 (20)

35 (33)

Lung Function (post-BD), mean (SD)

 FEV1%predicted

56.9 (21.8)

57.4 (16.4)

 RV % predicted

144.3 (49.4)

136.6 (46.7)

 TLC %predicted

110.5 (20.5)

107.9 (20.5)

 DLCO% predicted

61.0 (22.8)

57.7 (18.5)

 FEV1/FVC

46.9 (14.1)

46.9 (13.1)

Questionnaire scores, mean (SD)

 GerdQ

2.1 (3.3)

2.1 (3.2)

 Leicester cough

96.5 (38.0)

104.6 (27.1)

 RSI

10.0 (9.2)

10.1 (8.4)

[B]

Parameter

Pre-defined cohort with 2-year follow-up

(n = 107)

Beta

95% CI: Lower

95% CI: Upper

p-value

Age

0.239

0.006

0.050

0.013

6MWT

−0.073

−0.002

0.001

0.474

BODE Index

0.004

−0.099

0.103

0.969

Lung Function

 FEV1% predicted

−0.010

−0.013

0.012

0.923

 TLC % predicted

−0.182

−0.019

0.001

0.091

 RV % predicted

−0.142

−0.007

0.001

0.177

Νumber of exacerbations during the study

0.015

−0.175

0.205

0.877

Number of severe exacerbations during the study

−0.011

−0.305

0.272

0.911

Questionnaires

 GerdQ

−0.257

−0.139

− 0.022

0.008

 Leicester cough

0.012

−0.007

0.008

0.899

 RSI

−1.013

−0.034

0.011

0.314

  1. 95% CI 95% confidence interval, BMI body mass index, GERD gastroesophageal reflux disease, PPI proton pump inhibitors, GOLD Global Initiative for Chronic Obstructive Lung Disease, LABA long acting beta 2 agonist, LABA + ICS long-acting beta 2 agonist plus glucocorticosteroids, LAMA long-acting muscarinic antagonist, SABA short-acting beta 2 agonist, SAMA short-acting muscarinic antagonist, post-BD post-bronchodilator, FEV1 forced expiratory volume in 1 s, RV residual volume, TLC total lung capacity, DLCO diffusing capacity of the lung for carbon monoxide, GerdQ gastroesophageal reflux disease questionnaire, RSI Reflux symptom index, BODE Index Body mass, airflow obstruction, dyspnea and exercise capacity index, 6MWT 6-min walking test